SCHEMBL3763277

SCHEMBL3763277

O=C(O)N1CCN(c2nc(-c3ccccc3)ns2)CC1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FAAH O00519 17/20 0.73
NPC1 O15118 1/20 0.70
RAB9A P51151 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1164398 0.84 FAAH (1.00) FAAH
SCHEMBL3772029 0.84 FAAH (0.54) FAAHNPC1RAB9A
SCHEMBL3768360 0.83 NPC1 (0.70) FAAHNPC1RAB9A
SCHEMBL3769549 0.83 FAAH (0.53) FAAHNPC1RAB9A
SCHEMBL3771749 0.83 FAAH (0.59) FAAHNPC1RAB9A
SCHEMBL3772039 0.83 FAAH (0.62) FAAHNPC1RAB9A
SCHEMBL4466434 0.82 FAAH (0.91) FAAH
SCHEMBL3146042 0.82 FAAH (0.61) FAAHNPC1RAB9A
SCHEMBL3763247 0.81 FAAH (1.00) FAAHNPC1RAB9A
SCHEMBL3771787 0.81 FAAH (0.72) FAAHNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US claimed
WO-2007005510-A1 N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-11 WO claimed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US claimed
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed
WO-2007005510-A1 N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-11 WO disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 FAAH 1/4885NPC1 1078/4885RAB9A 1416/4885
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase FAAH, FAAH2, CNR2 FAAH 1/4885NPC1 1078/4885RAB9A 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.